10:56 AM
 | 
May 11, 2018
 |  BC Week In Review  |  Company News  |  Deals

Luye acquires AstraZeneca antipsychoitic for $538M

AstraZeneca plc (NYSE:AZN; LSE:AZN) granted Luye Pharma Group Ltd. (HKSE:2186) territorial rights to antipsychotic drug Seroquel quetiapine fumarate and its extended release formulation, Seroquel XL. Luye received rights in 51 countries and regions including China, the U.K., Brazil, Australia, Saudi Arabia, Mexico, South Korea, Thailand, Argentina, Malaysia and South Africa.

AstraZeneca is to receive $538 million, payable in three installments, according to a Luye regulatory filing in Hong Kong. The deal includes $260 million upon the deal's...

Read the full 363 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >